Development of ²²⁵Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences

Title:Development of ²²⁵Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences

Volume: 11 Issue: 3

Author(s): Andrew Kyle Henderson Robertson, Caterina Fortunata Ramogida, Paul Schaffer and Valery Radchenko*

Affiliation:

• Life Sciences Division, TRIUMF, Vancouver BC,Canada

Keywords: Actinium-225, targeted alpha therapy, isotope production, radiochemistry, radiolabeling, TRIUMF.

Abstract: Background: The development of radiopharmaceuticals containing 225Ac for targeted alpha therapy is an active area of academic and commercial research worldwide.

Objectives: Despite promising results from recent clinical trials, 225Ac-radiopharmaceutical development still faces significant challenges that must be overcome to realize the widespread clinical use of 225Ac. Some of these challenges include the limited availability of the isotope, the challenging chemistry required to isolate 225Ac from any co-produced isotopes, and the need for stable targeting systems with high radiolabeling yields.

Results: Here we provide a review of available literature pertaining to these challenges in the 225Acradiopharmaceutical field and also provide insight into how performed and planned efforts at TRIUMF - Canada’s particle accelerator centre - aim to address these issues.

Cite this article as:

Robertson Kyle Henderson Andrew , Ramogida Fortunata Caterina , Schaffer Paul and Radchenko Valery *, Development of ²²⁵Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences, Current Radiopharmaceuticals 2018; 11 (3) . https://dx.doi.org/10.2174/1874471011666180416161908